We just concluded a defining year for Golden Helix. 2025 was about execution at scale. With major platform releases, national-level adoption, and meaningful progress across pharmacogenomics, oncology, and long-read sequencing, we strengthened our position as a trusted clinical genomics platform for laboratories operating in regulated, high-throughput environments. Below, we reflect on the key accomplishments of 2025 and outline our focus for 2026.
Key Accomplishments in 2025
1. Platform Inflection: VarSeq 3.0 and VSWarehouse 3.0
In 2025, we released VarSeq 3.0 and VSWarehouse 3.0, marking a significant platform inflection point.
These releases expanded our deployment flexibility while preserving the robustness that enterprise and clinical customers expect:
- On-prem and cloud support: Golden Helix continues to set the standard for on-premises clinical genomics, while extending full support for cloud deployments on AWS and Azure. Customers can now choose the deployment model that best aligns with their operational, security, and regulatory requirements.
- Enterprise-grade capabilities for smaller labs: With the introduction of a sample-based licensing model, smaller and growing laboratories gained access to our full enterprise software stack. We are removing traditional barriers to advanced clinical genomics infrastructure.
Together, these advancements enable laboratories of all sizes to deploy Golden Helix software with confidence, flexibility, and long-term scalability.
2. National-Scale Deployment: Denmark
A defining milestone in 2025 was the announcement of our nationwide deployment in Denmark. This agreement represents more than a commercial success. It is proof of trust on a national scale. Supporting a country-wide genomics initiative requires:
- Proven clinical reliability
- Regulatory readiness
- Scalable infrastructure
- Long-term platform stability
Denmark’s selection of Golden Helix underscores our ability to meet these demands and operate as a strategic partner in population-scale genomics programs.
3. Long-Read Sequencing: Production-Ready Support
In 2025, we made substantial advances in our support for long-read sequencing technologies, including PacBio and Oxford Nanopore. Key improvements included:
- Enhanced handling of long-read variant data
- Improved workflows for complex variant types such as structural variants, repeat expansions and methylation
- Stronger support for hybrid short- and long-read use cases
These enhancements allow laboratories to confidently integrate long-read sequencing into clinical and translational workflows, rather than treating it as a purely exploratory technology.
4. Oncology: Advancing Clinical Knowledge and Interpretation
We delivered a major uplift to the Golden Helix Cancer Knowledge Base, significantly strengthening its prognostic and diagnostic capabilities. This work focused on:
- Deeper curation and refinement of cancer-relevant variants
- Improved clinical interpretation support
- Alignment with evolving oncology standards
These improvements further reduce manual burden for laboratories while increasing consistency and clinical confidence in somatic variant interpretation.
5. Pharmacogenomics: NIH SBIR Award
In 2025, Golden Helix was awarded a $2.2 million SBIR grant from the NIH to advance our pharmacogenomics platform. This funding validates both the clinical importance of pharmacogenomics and our technical approach. It accelerates our ability to deliver scalable PGx solutions that integrate seamlessly into broader genomic testing workflows.
Our Focus for 2026
With a strong execution foundation in place, our 2026 roadmap centers on three innovation pillars: Clinical Yield, Automation, and Scalability.
1. Clinical Yield
In 2026, we will focus on extracting more clinically meaningful insight from genomic data. Key initiatives include:
- Improved splice site prediction, enhancing the interpretation of variants with complex functional impact
- Deeper integration with premium knowledge sources, including Genomenon Mastermind, CKB, and continued expansion of the Golden Helix Cancer Knowledge Base
- More comprehensive synthesis of variant evidence to support confident clinical decision-making
Our goal is not more data, but better answers.
2. Automation
Automation remains essential to scaling clinical genomics responsibly. In 2026, we will continue to invest in:
- Enhanced auto-classifiers, reducing manual interpretation effort while maintaining transparency and auditability
- Adherence to evolving guidelines, ensuring workflows remain aligned with new and updated clinical standards
- Controlled, targeted AI assistance, applied selectively and deliberately to support, but not replace, expert review
All automation efforts will remain grounded in regulatory expectations and clinical accountability.
3. Scalability
As genomics programs grow, software must scale not only technically, but organizationally. Our 2026 scalability initiatives include:
- Continued improvements to the underlying data infrastructure, supporting higher throughput and larger datasets
- Expanded role-based access and workflows, reflecting the division of labor in large, multi-disciplinary laboratories
- Enterprise features designed to support collaboration, oversight, and interoperability at scale
These investments ensure that Golden Helix remains a stable, long-term platform as customer needs evolve.
Looking Ahead
The thread connecting our 2025 accomplishments and 2026 priorities is trust. It is earned through execution, transparency, and clinical rigor.
Whether supporting national genomics initiatives, enabling enterprise-scale laboratories, or helping smaller labs access advanced capabilities, our mission remains unchanged: to deliver clinical genomics software that laboratories can rely on. Today and for the long term.
We look forward to continuing this journey with our customers, partners, and collaborators in 2026.
